{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Bermudo-Peloche G"],"funding":["CERCA Program","Roche","Instituto de Salud Carlos III"],"pagination":["2402249"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12018760"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["65(4)"],"pubmed_abstract":["<h4>Background</h4>Patients with severe COVID-19 may develop lung fibrosis. Pirfenidone is an anti-fibrotic drug approved for idiopathic pulmonary fibrosis. The efficacy and safety of pirfenidone in patients with fibrotic interstitial lung changes after recovery from severe COVID-19 pneumonia were evaluated.<h4>Methods</h4>This was a phase 2, double-blind, placebo-controlled, Spanish multicentre clinical trial. Patients were randomised to receive pirfenidone or placebo (2:1) for 24 weeks. The primary end-point was the proportion of patients that improved, considered when percentage change in forced vital capacity (FVC) was ≥10% and/or any reduction in the fibrotic score on chest high-resolution computed tomography (HRCT). Secondary end-points included health-related quality of life (HRQoL)"],"journal":["The European respiratory journal"],"pubmed_title":["Pirfenidone in post-COVID-19 pulmonary fibrosis (FIBRO-COVID): a phase 2 randomised clinical trial."],"pmcid":["PMC12018760"],"funding_grant_id":["PI21/01287"],"pubmed_authors":["Santos-Perez S","Hereu P","Vicens-Zygmunt V","Balcells E","Valenzuela C","Lopez Ramirez C","Fuentes M","Blavia R","Montes-Worboys A","Del Rio B","Badenes-Bonet D","Sellares J","Gutierrez-Rodriguez Y","Caballero P","Sanz-Santos J","Caupena C","Castillo D","Molina-Molina M","Ferrer-Artola A","Franquet T","Segovia P","Bordas-Martinez J","Hernandez M","Penafiel J","Bolivar S","Millan-Billi P","Tomas L","Fernandez de Roitegi K","Gonzalez J","Luburich P","Bermudo-Peloche G","Badia MB","Portillo K","Alarcon J","Rodriguez-Portal JA","Laporta R","Rigual Bobillo J","Barril S"],"additional_accession":[]},"is_claimable":false,"name":"Pirfenidone in post-COVID-19 pulmonary fibrosis (FIBRO-COVID): a phase 2 randomised clinical trial.","description":"<h4>Background</h4>Patients with severe COVID-19 may develop lung fibrosis. Pirfenidone is an anti-fibrotic drug approved for idiopathic pulmonary fibrosis. The efficacy and safety of pirfenidone in patients with fibrotic interstitial lung changes after recovery from severe COVID-19 pneumonia were evaluated.<h4>Methods</h4>This was a phase 2, double-blind, placebo-controlled, Spanish multicentre clinical trial. Patients were randomised to receive pirfenidone or placebo (2:1) for 24 weeks. The primary end-point was the proportion of patients that improved, considered when percentage change in forced vital capacity (FVC) was ≥10% and/or any reduction in the fibrotic score on chest high-resolution computed tomography (HRCT). Secondary end-points included health-related quality of life (HRQoL)","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Apr","modification":"2026-07-15T05:42:52.577Z","creation":"2026-07-01T03:07:06.218Z"},"accession":"S-EPMC12018760","cross_references":{"pubmed":["40154560"],"doi":["10.1183/13993003.02249-2024"]}}